SARS-CoV-2 spike glycoprotein-reactive T cells can be readily expanded from COVID-19 vaccinated donors,Immunity, Inflammation and Disease

当前位置： X-MOL 学术 › Immun. Inflamm. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

SARS-CoV-2 spike glycoprotein-reactive T cells can be readily expanded from COVID-19 vaccinated donors
Immunity, Inflammation and Disease ( IF 3.1 ) Pub Date : 2021-07-27 , DOI: 10.1002/iid3.496
Pavla Taborska ₁ , Jan Lastovicka ₁ , Dmitry Stakheev ₁ , Zuzana Strizova ₁ , Jirina Bartunkova ₁ , Daniel Smrz ₁

Affiliation

The COVID-19 vaccine was designed to provide protection against infection by the severe respiratory coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19). However, the vaccine's efficacy can be compromised in patients with immunodeficiencies or the vaccine-induced immunoprotection suppressed by other comorbidity treatments, such as chemotherapy or immunotherapy. To enhance the protective role of the COVID-19 vaccine, we have investigated a combination of the COVID-19 vaccination with ex vivo enrichment and large-scale expansion of SARS-CoV-2 spike glycoprotein-reactive CD4⁺ and CD8⁺ T cells.

中文翻译：

SARS-CoV-2 刺突糖蛋白反应性 T 细胞可以很容易地从 COVID-19 疫苗接种的供体中扩增

COVID-19 疫苗旨在提供针对严重呼吸道冠状病毒 2 (SARS-CoV-2) 和冠状病毒病 2019 (COVID-19) 感染的保护。然而，在免疫缺陷患者或疫苗诱导的免疫保护被其他合并症治疗（如化学疗法或免疫疗法）抑制的患者中，疫苗的功效可能会受到影响。为了增强 COVID-19 疫苗的保护作用，我们研究了 COVID-19 疫苗接种与离体富集和大规模扩增 SARS-CoV-2 刺突糖蛋白反应性 CD4 ⁺和 CD8 ⁺ T 细胞的组合。

更新日期：2021-07-27

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文